CAR-T for DLBCL: Treatment Routes, Country Comparison, and Global Access Guide (2026)
Find the right CAR-T treatment path for relapsed/refractory DLBCL based on your eligibility, budget, urgency, and destination country.
Why DLBCL Requires CAR-T Decision
DLBCL (Diffuse Large B-Cell Lymphoma) is the most common B-cell NHL subtype. When DLBCL becomes relapsed or refractory after 2 lines of therapy, CAR-T becomes the primary decision point.
Why This Matters: After 2 failed therapies, DLBCL patients face a critical decision: CAR-T eligibility. Choosing the wrong country or hospital can delay treatment by 2–3 months, which impacts survival outcomes. This page helps you make the right choice quickly.
DLBCL Treatment Pathways (2026)
CAR-T is the only path with 80-85% ORR for relapsed/refractory DLBCL.
| Treatment Path | Best For | CAR-T Eligible | Best Countries | Budget | Time | Urgency |
|---|---|---|---|---|---|---|
| CAR-T (CD19) | Relapsed/refractory after 2 therapies | ✅ Yes | 🇰🇷 Korea, 🇩🇪 Germany, 🇮🇳 India, 🇨🇳 China | $40K-$440K | 4-6 w | High |
| Immunotherapy | First-line or early relapse | ❌ No | 🇮🇳 India, 🇨🇳 China, 🇰🇷 Korea | $5K-$20K | 2-4 w | Medium |
| Transplant | Patients not eligible for CAR-T | ❌ No | 🇩🇪 Germany, 🇰🇷 Korea, 🇸🇬 Singapore | $20K-$60K | 2-4 w | High |
| Chemotherapy | Palliative control | ❌ No | 🇮🇳 India, 🇨🇳 China, 🇰🇷 Korea | $1.2K-$6.4K | 1-2 w | High |
CAR-T Route Cards: 4 Countries Compared
Side-by-side comparison of CAR-T access, cost, ORR, and access time for DLBCL patients.
India BEST VALUE
Tata Memorial, Apollo Chennai, AIIMS Delhi
South Korea
Asan Hospital, Seoul National University Hospital
Germany
Charité Berlin (1,200+ CAR-T), CCC Heidelberg, LMU Munich
China
CARsgen, Peking University Cancer Hospital
DLBCL Decision Matrix
Choose your CAR-T destination based on budget, speed, and care preferences.
| Your Situation | Best Country | CAR-T Cost | Time | Why |
|---|---|---|---|---|
| Budget < $100K | 🇮🇳 India | $45K-$85K | 2-4 w | Lowest cost, 80-85% ORR |
| Budget $100K-$200K | 🇰🇷 Korea | $120K-$180K | 3-5 w | Mid cost, 80-85% ORR |
| Budget > $300K | 🇩🇪 Germany | €320K-€440K | 4-6 w | Premium, EMA-approved |
| Want Trial Access | 🇨🇳 China | $40K-$80K | 4-6 w | Trial CAR-T, 70-80% ORR |
| Need Fastest Access | 🇮🇳 India | $45K-$85K | 2-4 w | 2x faster than Korea/Germany |
| Need Premium Care | 🇩🇪 Germany | €320K-€440K | 4-6 w | Charité Berlin (1,200+ CAR-T) |
Real DLBCL CAR-T Patient Stories
How country selection and CAR-T access changed outcomes for DLBCL patients.
DLBCL Relapsed: MRD-Negative CR at Charité Berlin
Relapsed after 2 therapies. Received CD19 CAR-T (Yescarta, EMA-approved) at Charité Berlin.
DLBCL Relapsed: 86% Cheaper at Tata Memorial
Relapsed after 3 therapies. Received CD19 CAR-T (Yescarta) at Tata Memorial, India.
DLBCL Relapsed: 68% Cheaper at Asan Hospital
Relapsed after 2 therapies. Received CD19 CAR-T (Breyanzi) at Asan Hospital, Korea.
Disclaimer: This page is for decision support only, not a substitute for medical advice. Always consult your physician. Read our full Legal Framework →
CAR-T for DLBCL FAQ
Yes. CAR-T (CD19) is highly effective for relapsed/refractory DLBCL. ORR: 80-85%, CR rate: 70-75% at month 3, maintained at month 12. Best for patients who have failed 2+ lines of therapy.
Budget under $100K: India ($45K-$85K, fastest 2-4 weeks). Budget $100K-$200K: Korea ($120K-$180K, 3-5 weeks). Budget over $300K: Germany ($330K-$440K, premium EMA-approved). Trial access: China ($40K-$80K).
India: $45K-$85K (86% cheaper than US). Korea: $120K-$180K (68% cheaper). Germany: €320K-€440K/$330K-$440K (25-30% cheaper). China: $40K-$80K (80% cheaper). USA: $475K+.
4-6 weeks total (from contact to infusion). India: 2-4 weeks (fastest). Korea: 3-5 weeks. Germany: 4-6 weeks. China: 4-6 weeks.
Medical letter (diagnosis, DLBCL, relapsed/refractory), pathology report (CD19+, NGS), imaging (CT/PET-CT), treatment history, passport, flight ticket, hotel booking, payment proof, and visa.
Germany: Charité Berlin (1,200+ CAR-T treatments, Europe's largest). Korea: Asan Hospital, Seoul National University Hospital. India: Tata Memorial, Apollo Chennai. China: CARsgen.
Ready to Check Your CAR-T Eligibility?
Submit your case for a free, no-obligation assessment. Our hematology team will evaluate your DLBCL treatment history and match you with the optimal CAR-T destination within 48 hours.
Free • Confidential • 48-Hour Response • No Obligation